7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl: Evidence & Safety Comparison
Compare 7-hydroxymitragynine, MGM-15, and mitragynine pseudoindoxyl by chemical identity, opioid pharmacology, human evidence, and safety gaps without turning assay results into a universal potency ranking.
7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl: Evidence & Safety Comparison
Quick answer
7-hydroxymitragynine (7-OH), MGM-15 (dihydro-7-hydroxymitragynine), and mitragynine pseudoindoxyl are related to the kratom alkaloid pathway, but they are not interchangeable compounds. They differ in chemical identity, origin, metabolism, product context, and the amount of human evidence available.
All three have opioid-receptor pharmacology in preclinical systems, but there is no validated human “strongest to weakest” ranking that can be inferred from a single binding or signaling assay. Apparent potency can change with the receptor assay, endpoint, species, concentration, metabolism, and formulation being studied.
Evidence grade: Very Low for comparative human effects.
Important: Looking specifically for MGM-15? Use the dedicated MGM-15 / dihydro-7-hydroxymitragynine evidence review for identity, aliases, forensic alerts, human-data gaps, and safety context.
Why these compounds are compared
These three compounds are often discussed together because each is related to mitragynine chemistry and each can engage opioid receptors more strongly than the parent alkaloid in at least some laboratory systems. That biochemical relationship is useful for understanding risk, but it does not make them equivalent exposures.
A safer comparison asks four separate questions:
- What exactly is the compound?
- What do laboratory receptor assays show?
- What human exposure or clinical evidence exists?
- What can actually be concluded about real-world safety and dependence?
Chemical identity
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Compound | What it is | Relationship to kratom |
|---|---|---|
| 7-Hydroxymitragynine (7-OH) | Oxidized kratom alkaloid / active metabolite | Can occur at low levels and can also be formed metabolically from mitragynine |
| MGM-15 | Dihydro-7-hydroxymitragynine; semi-synthetic derivative | Not a normal traditional whole-leaf constituent; encountered as an emerging derivative |
| Mitragynine pseudoindoxyl | Rearrangement/metabolite-related compound | Distinct downstream compound with its own pharmacology and product context |
The practical point is simple: “kratom-derived” does not mean “the same as kratom leaf.” A concentrated or semi-synthetic derivative can create a very different exposure from a botanical preparation.
What the pharmacology shows — and what it does not
All three compounds demonstrate opioid-receptor activity in laboratory systems. Published studies report high mu-opioid receptor activity for 7-OH and mitragynine pseudoindoxyl, while MGM-15 and related dihydro derivatives have also shown substantial opioid-receptor activity in preclinical medicinal-chemistry work.
What should not be done is to merge numbers from different assays into a universal potency ladder. Receptor affinity, G-protein signaling, beta-arrestin signaling, animal antinociception, and human subjective effects are different endpoints.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Question | What can be said responsibly? |
|---|---|
| Which binds most tightly in one specific assay? | Depends on the assay and paper being cited. |
| Which is “strongest” in a person? | Not established by controlled comparative human studies. |
| Which has the most human evidence? | 7-OH currently has more direct human-safety and exposure context than MGM-15; MGM-15 remains especially poorly characterized. |
| Can receptor potency predict overdose risk precisely? | No. Exposure, metabolism, formulation, co-use, tolerance, and product identity all matter. |
Human evidence is the real bottleneck
Comparative human evidence is extremely limited. Most claims about these compounds come from in-vitro pharmacology, animal research, forensic testing, case reports, or product surveillance.
7-Hydroxymitragynine
7-OH has the largest human-relevance evidence base of the three, including growing toxicology, market, and withdrawal-related reporting. Even so, controlled human dose-response and safety data remain limited relative to approved medicines.
MGM-15
MGM-15 has the least mature human evidence base. Forensic alerts establish market presence, while controlled human pharmacokinetic, safety, dependence, withdrawal, and overdose studies are lacking.
Read the full MGM-15 evidence review.
Mitragynine pseudoindoxyl
Mitragynine pseudoindoxyl has substantial preclinical pharmacology and emerging real-world product and withdrawal context, but controlled human clinical characterization remains incomplete.
Read the full mitragynine pseudoindoxyl review.
Safety and dependence
These are opioid-acting compounds or derivatives. Important risks can include respiratory depression, severe sedation, physical dependence, withdrawal, impaired driving, overdose, and dangerous interactions with other central nervous system depressants.
Risk is harder to estimate when products are unregulated because:
- the label may not match the actual compound or concentration;
- multiple active derivatives may be present together;
- contaminants or other sedatives may be present;
- users may assume a semi-synthetic derivative has the same risk profile as ordinary kratom leaf;
- laboratory identification can be technically difficult without appropriate standards.
Why this page does not publish a universal potency ranking
Earlier versions of this comparison used a simplified “potency ranking.” That framing was too broad because different sections could imply different orders depending on which laboratory endpoint was being referenced.
A better rule is:
Potency claims must stay attached to the assay that generated them. A receptor-binding result, signaling assay, animal pain model, and real-world human exposure are not interchangeable measures.
Until controlled comparative human studies exist, a single strongest-to-weakest ordering would create more confidence than the evidence supports.
Harm-reduction interpretation
- Treat each compound as a distinct exposure.
- Do not infer a safe dose from receptor assays or anecdotal potency comparisons.
- Product composition and concentration may be inaccurate or variable.
- Combining opioid-active products with alcohol, benzodiazepines, gabapentinoids, sleep medications, other opioids, or sedatives can increase risk.
- Severe sedation, slowed breathing, blue lips, collapse, seizures, or loss of consciousness require urgent medical evaluation.
Full monographs
For the detailed pharmacology, evidence, and safety write-up of each compound:
Related reading
- Substance Use, Dependence & Harm Reduction hub
- Kratom-derived semi-synthetic opioids
- Harm reduction considerations
- Novel psychoactive substances overview
Search methodology
This comparison prioritizes peer-reviewed pharmacology, forensic reports, public-health surveillance, and direct human evidence when available. Laboratory potency claims are kept tied to their original assay rather than converted into a universal human ranking.